Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens

Sarah M Kashanian¹, Noa G Holtzman^{2

3}, Ciera L Patzke^{3

4}, Jonathan Cornu⁴, Alison Duffy^{3

4

5}, Madhurima Koka⁶, Sandrine Niyongere^{1

3}, Vu H Duong^{1

3}, Maria R Baer^{1

3}, Jummai Apata⁷, Farin Kamangar⁸, Ashkan Emadi^{9

10

11}

Affiliations

¹ Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
² Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
³ Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, Room N9E06, Baltimore, MD, 21201, USA.
⁴ Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD, USA.
⁵ University of Maryland School of Pharmacy, Baltimore, MD, USA.
⁶ Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
⁷ Center for Urban Health Disparities Research and Innovation, Morgan State University, Baltimore, MD, USA.
⁸ Department of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, MD, USA.
⁹ Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. aemadi@umm.edu.
¹⁰ Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, Room N9E06, Baltimore, MD, 21201, USA. aemadi@umm.edu.
¹¹ Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA. aemadi@umm.edu.

PMID: 33677674
DOI: 10.1007/s00280-021-04252-y

Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens

Sarah M Kashanian et al. Cancer Chemother Pharmacol. 2021 Jun.

. 2021 Jun;87(6):817-826.

doi: 10.1007/s00280-021-04252-y. Epub 2021 Mar 7.

Authors

Affiliations

¹ Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
² Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
³ Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, Room N9E06, Baltimore, MD, 21201, USA.
⁴ Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD, USA.
⁵ University of Maryland School of Pharmacy, Baltimore, MD, USA.
⁶ Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
⁷ Center for Urban Health Disparities Research and Innovation, Morgan State University, Baltimore, MD, USA.
⁸ Department of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, MD, USA.
⁹ Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. aemadi@umm.edu.
¹⁰ Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, Room N9E06, Baltimore, MD, 21201, USA. aemadi@umm.edu.
¹¹ Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA. aemadi@umm.edu.

PMID: 33677674
DOI: 10.1007/s00280-021-04252-y

Abstract

Purpose: Asparaginases, key agents in treatment of acute lymphoblastic leukemia (ALL), are associated with venous thromboembolism (VTE). While risks of short-acting asparaginase-related VTE is well-known, we studied VTE incidence and risk factors in adult ALL patients treated with and without long-acting pegylated asparaginase (PegA).

Methods: Single-center, retrospective analysis of 89 ALL patients treated with (n = 61) or without (n = 28) PegA at Greenebaum Comprehensive Cancer Center. Reviewed patient and disease characteristics, treatment, and VTE incidence.

Results: VTE during treatment occurred in 31 patients (35%), and was associated with PegA (p = 0.001) and Philadelphia chromosome negativity (p = 0.002). Among PegA recipients, VTE was associated with a significantly higher mean body mass index (BMI) of 31.3 kg/m² (p = 0.037), and was more common with pre-T/T cell compared to pre-B/B cell ALL (68.2% vs. 33.3%, p = 0.009). Antithrombin-III (ATIII) levels were measured for 26 patients; 16 (61.5%) were < 50%. Of those, 8 (50%) experienced VTE, while 3 of 10 (30%) patients with ATIII levels ≥ 50% experienced VTE. VTE occurred in 7 of 13 (54%) of patients who received ATIII repletion. There was a trend toward a higher incidence of VTE in the PegA group among patients with non-O compared to O blood type (55.9% vs. 33.3%, p = 0.079) as well as those with a higher hemoglobin at diagnosis (9.3 vs 8.1 g/dL, p = 0.056).

Conclusion: This study confirms PegA as a risk factor for VTE in patients with ALL. Risk factors among those receiving PegA include higher BMI and pre-T/T cell ALL. ATIII repletion was not shown to be protective against VTE. There was a higher incidence of VTE in patients who received PegA with non-O compared to O blood type, but the precise correlation is uncertain.

Keywords: ALL; Acute lymphoblastic leukemia; Pegaspargase; Pegylated-asparaginase; Venous thromboembolism.

PubMed Disclaimer

References

1. Siegel SE, Advani A, Seibel N et al (2018) Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens. Am J Hematol 93:1254–1266. https://doi.org/10.1002/ajh.25229 - DOI - PubMed - PMC
1. DeAngelo DJ, Stevenson KE, Dahlberg SE et al (2015) Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 29:526–534. https://doi.org/10.1038/leu.2014.229 - DOI - PubMed
1. Lu C, Karp J, Emadi A (2020) Antimetabolites: hydroxyurea, pyrimidine and purine analogs, and L-asparaginase. In: Emadi A, Karp JE (eds) Cancer pharmacology: an illustrated manual of anticancer drugs. Demos Medical, New York
1. Avramis VI, Sencer S, Periclou AP et al (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 99:1986–1994. https://doi.org/10.1182/blood.V99.6.1986 - DOI - PubMed
1. Place AE, Stevenson KE, Vrooman LM et al (2015) Intravenous pegylated asparaginase versus intramuscular native Escherichia coliL-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05–001): a randomised, open-label phase 3 trial. Lancet Oncol 16:1677–1690. https://doi.org/10.1016/S1470-2045(15)00363-0 - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

P30CA134274/University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens

Affiliations

Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources